Douglas Cartwright

Douglas Cartwright serves as a Clinical Lecturer in Medical Oncology at the University of Glasgow, based at Clinical Research Gartnavel. His clinical and research activities focus on two primary disease domains:

• Lung Cancer: Specializing in pleural malignancy diagnostics and immunotherapy pathway analysis
• Gynaecological Cancers: With concentrated expertise in ovarian and uterine malignancies, metastasis mechanisms, and targeted therapies

His work bridges clinical oncology practice with translational research to address unmet therapeutic needs.

Dr. Cartwright's research program integrates molecular oncology, clinical genomics, and metastasis biology through key initiatives:

• Investigation of oncogenic signalling-immunotherapy crosstalk (2025)
• Development of genomic decision support tools for Scottish breast cancer care (2024)
• Creation of physiologically relevant ovarian cancer metastasis models using omentum-derived matrices (2023)
• Clinical evaluation of PARP inhibitors for ovarian cancer brain metastases (2023)

This multidisciplinary approach aims to translate laboratory discoveries into precision oncology applications for challenging clinical scenarios.

Analysis of his publication record (2019-2025) reveals three dominant research streams: (1) biomarker development for cancer diagnostics and treatment selection, (2) mechanisms of metastasis in gynaecological cancers, and (3) optimization of immunotherapy through signalling pathway understanding. His work consistently emphasizes clinically actionable solutions with increasing focus on genomic and immunological approaches to personalize solid tumor management.

No scientific awards, fellowships, or major honors were documented in the provided materials.

While specific student mentorship details were not disclosed, Dr. Cartwright's collaborative publication pattern across multiple institutions indicates active participation in multidisciplinary research networks. Information regarding current research grants was not specified in the source documentation.

He contributes to the University of Glasgow's Lung and Gynaecological Cancer Research Groups, where his team develops innovative translational models including omentum-derived matrices to study tumor-stromal interactions in metastatic environments and test novel therapeutic interventions.